The Vaccine Contract Manufacturing Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Factors Such As Reduced Market Time, Infrastructure Cost Benefits, And Operational Benefits Are Driving The Market Growth
Some of the major forces propelling the global vaccine contract manufacturing market include reduced market time, infrastructure cost, and operational benefits. Furthermore, technical advancements such as the development of new expression systems like GPEx and EB66 cell lines and cell culture medium platforms are expected to propel market growth. On the other hand, few large organizations consider outsourcing to be harmful due to the loss of strategic and management control. Considerable investments in facilities, equipment, and skilled labour in countries looking to grow or localise their supply are expected to impact contract services adoption positively. In addition, several low-resource countries lack the requisite equipment and experienced personnel to manufacture vaccines, leading them to create contracts with contract producers to meet market demand.
On the other hand, few large organizations see outsourcing as a concern since it results in a loss of strategic and management control. As a result, big pharmaceutical companies prefer to maintain their manufacturing in-house. This aspect is predicted to hinder global acceptance of contract services over the forecast period.
Logistical And Administrative Challenges
Local governments will need a robust data infrastructure to identify eligible persons by priority group, make invites, organise transportation for elderly and disabled patients, and recall individuals to obtain second doses of particular vaccines. Several of the most promising vaccine ideas necessitate ultra-cold chains and have a short shelf life once extracted from storage. BioNTech and Pfizer's mRNA vaccines, for example, must be administered within five days of leaving ultra-low temperature settings (–70°C); Moderna's mRNA vaccine has similar, if less stringent, restrictions. Strong coordination between central depots & local vaccinators would be necessary to ensure the timely & effective delivery of mRNA vaccine batches to regions without freezers.
What Are These Questions You Should Ask Before Buying A Market Research Report?
• How is the vaccine contract manufacturing market evolving?
• What is driving and restraining the vaccine contract manufacturing market?
• How will each vaccine contract manufacturing submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
• How will the market shares for each vaccine contract manufacturing submarket develop from 2022 to 2032?
• What will be the main driver for the overall market from 2022 to 2032?
• Will leading vaccine contract manufacturing markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
• Who are the leading players and what are their prospects over the forecast period?
• What are the vaccine contract manufacturing projects for these leading companies?
• How will the industry evolve during the period between 2020 and 2032? What are the implication of vaccine contract manufacturing projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the vaccine contract manufacturing market?
• Where is the vaccine contract manufacturing market heading? And how can you ensure you are at the forefront of the market?
• What can be the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path? C-suite?
You need to discover how this will impact the vaccine contract manufacturing market today, and over the next 10 years:
• Our 565-page report provides 377 tables and 379 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• Contains in-depth analyse of global, regional and national sales and growth
• Highlights for you the key successful trends, changes and revenue projections made by your competitors
This report tells you TODAY how the vaccine contract manufacturing market will develop in the next 10 years, and in-line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2032 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising vaccine contract manufacturing prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, V, L, W and U are discussed in this report.
Segments Covered in the Report
Process Outlook
• Upstream Process
- Mammalian Expression Vaccine
- Bacterial Expression Vaccine
- Yeast Expression Vaccine
- Baculovirus/Insect Expression Vaccine
- Other Upstream
• Downstream Process
- Fill & Finish Operations
- Analytical & QC Studies
- Vaccine Packaging
Type
• Subunit Vaccines
• Live Attenuated Vaccines
• Conjugate Vaccines
• Inactivated Vaccines
• Recombinant Vector Vaccines
• Other Vaccine Type
Company Size
• Small Manufacturers
• Mid-sized Manufacturers
• Large Manufacturers
• Very Large Manufacturers
Operation
• Preclinical
• Clinical
• Commercial
• Other Operations
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 4 regional and 20 leading national markets:
North America
• U.S.
• Canada
• Mexico
Europe
• Germany
• Spain
• United Kingdom
• France
• Italy
• Rest of Europe
Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific
LAMEA
• Brazil
• Turkey
• Saudi Arabia
• South Africa
• UAE
• Rest of Latin America
The report also includes profiles and for some of the leading companies in the Vaccine Contract Manufacturing Market, 2022 to 2032, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
• AbbVie Inc. (AbbVie)
• Bavarian Nordic A/S
• Catalent, Inc.
• Charles River Laboratories International, Inc.
• Emergent BioSolutions Inc.
• Eurofins Scientific SE
• FUJIFILM Holdings Corporation
• GlaxoSmithKline PLC
• Kemwell Biopharma
• Lonza Group AG (Lonza)
• Merck KGaA
• Pfizer Inc. (Pfizer)
• Richter-Helm BioLogics
• Samsung Biologics Co Ltd
• Sanofi SA
• Serum Institute of India
• Siegfried Holding AG
• Thermo Fisher Scientific Inc.
• Wacker Biotech B.V
• WuXi Biologics Cayman Inc
Overall world revenue for Vaccine Contract Manufacturing Market, 2022 to 2032 in terms of value the market will surpass US$2,676 million in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Vaccine Contract Manufacturing Market, 2022 to 2032 Market report helps you?
In summary, our 560+ page report provides you with the following knowledge:
• Revenue forecasts to 2032 for Vaccine Contract Manufacturing Market, 2022 to 2032 Market, with forecasts for Process, upstream, downstream, type company size each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2032 for 4 regional and 20 key national markets – See forecasts for the Vaccine Contract Manufacturing Market, 2022 to 2032 market in North America, Europe, Asia-Pacific and LAMEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 20 of the major companies involved in the Vaccine Contract Manufacturing Market, 2022 to 2032 Market.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Vaccine Contract Manufacturing Market, 2022 to 2032 Market and leading companies. You will find data, trends and predictions.
'
1. Report Overview
1.1 Introduction to Vaccine Contract Manufacturing Market
1.2 Global Vaccine Contract Manufacturing Market Overview
1.3 What are the Objectives of this Report?
1.4 What is the Scope of the Report?
1.5 Why You Should Read This Report
1.6 What This Report Delivers
1.7 Key Questions Answered By This Analytical Report Include:
1.8 Who is This Report for?
1.9 Research Methodology
1.9.1 Primary Research
1.9.2 Secondary Research
1.9.3 Market Evaluation & Forecasting Methodology
1.10 Frequently Asked Questions (FAQs)
1.11 Associated Reports
1.12 About
2 Executive Summary
3 Global Market Dynamics
3.1 COVID-19 Impact on Global Market:
3.2 Current Trends in the Global Market
3.3 Market Driving Factors
3.3.1 Growth In Infectious Diseases
3.3.2 Stakeholder Cooperation Maximises Manufacturing Capacity
3.3.3 Implications Beyond COVID-19
3.4 Market Restraining Factors
3.4.1 Material And Equipment Shortages
3.4.2 Manufacturing Process Complexity
3.4.3 Capacity Constraints
3.5 Opportunities in the Global Market
3.5.1 New Vaccine Technologies
3.5.1.1 Gene-based vaccines
3.5.1.2 VLPs
3.5.1.3 Plant-derived vaccines
3.5.1.4 Novel adjuvants and delivery systems.
3.6 Challenges in the Global Market
3.6.1 Unprecedented Vaccine Production Demand
3.6.2 Logistical And Administrative Challenges
3.6.3 Vaccine Hesitancy
3.7 SWOT Analysis
3.7.1 Strength
3.7.1.1 Growth In Infectious Diseases
3.7.1.2 Stakeholder Cooperation Maximises Manufacturing Capacity
3.7.1.3 Implications Beyond COVID-19
3.7.2 Weakness
3.7.2.1 Material And Equipment Shortages
3.7.2.2 Manufacturing Process Complexity
3.7.2.3 Capacity Constraints
3.7.3 Opportunities
3.7.3.1 New Vaccine Technologies
3.7.4 Threats
3.7.4.1 Unprecedented Vaccine Production Demand
3.7.4.2 Logistical And Administrative Challenges
3.7.4.3 Vaccine Hesitancy
3.8 PEST Analysis:
3.8.1 Political Factors
3.8.2 Economic Factors
3.8.3 Sociocultural Factors
3.8.4 Technological Factors
3.9 Porter’s Five Forces Analysis
3.9.1 What are Porter Five (5) Forces
3.9.2 Threat of New Entrants (Low to Moderate)
3.9.3 Rivalry Among the Existing Players (High)
3.9.4 Bargaining Power of Suppliers (Low)
3.9.5 Threats from Substitute Products (Low to Moderate)
3.9.6 Bargaining Power of Buyers (High)
4 Global Vaccine Contract Manufacturing Market Analysis
4.1 Global Market Outlook
4.2 Global Market Size Estimation and Forecast
4.2.1 Pre-COVID-19 Market Scenario
4.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
5 Global Vaccine Contract Manufacturing Market Analysis By Region
5.1 North America
5.2 Europe
5.3 Asia Pacific
5.4 LAMEA
5.5 Regional Market Size Estimation and Forecast
5.5.1 Pre-COVID-19 Market Scenario
5.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
6 Global Vaccine Contract Manufacturing Market Analysis By Process
6.1 Upstream Process
6.2 Downstream Process
6.3 Global Market Size Estimation and Forecast By Process
6.3.1 Pre-COVID-19 Market Scenario
6.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
7 Global Vaccine Contract Manufacturing Market Analysis By Downstream
7.1 Fill & Finish Operations
7.2 Analytical & QC Studies
7.3 Vaccine Packaging
7.4 Global Market Size Estimation and Forecast By Downstream
7.4.1 Pre-COVID-19 Market Scenario
7.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
8 Global Vaccine Contract Manufacturing Market Analysis By Upstream
8.1 Mammalian Expression Vaccine Type
8.2 Bacterial Expression Vaccine Type
8.3 Yeast Expression Vaccine Type
8.4 Baculovirus/Insect Expression Vaccine Type
8.5 Other Upstream Process
8.6 Global Market Size Estimation and Forecast By Upstream
8.6.1 Pre-COVID-19 Market Scenario
8.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
9 Global Vaccine Contract Manufacturing Market Analysis By Vaccine Type
9.1 Subunit Vaccines
9.2 Live Attenuated Vaccines
9.3 Conjugate Vaccines
9.4 Inactivated Vaccines
9.5 Recombinant Vector Vaccines
9.6 Other Vaccine Type
9.7 Global Market Size Estimation and Forecast By Vaccine Type
9.7.1 Pre-COVID-19 Market Scenario
9.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
10 Global Vaccine Contract Manufacturing Market Analysis By Company Size
10.1 Global Market Size Estimation and Forecast By Company Size
10.1.1 Pre-COVID-19 Market Scenario
10.1.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11 Global Vaccine Contract Manufacturing Market Analysis By Operation
11.1 Preclinical
11.2 Clinical
11.3 Commercial
11.4 Global Market Size Estimation and Forecast By Operation
11.4.1 Pre-COVID-19 Market Scenario
11.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12 North America Vaccine Contract Manufacturing Market Analysis
12.1 North American Countries Have The Most Demanding Legislation Regulating And Controlling Pharmaceuticals’ Distribution And Production
12.2 North America Market Size Estimation and Forecast
12.2.1 Pre-COVID-19 Market Scenario
12.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.3 Country Market Size Estimation and Forecast
12.3.1 Pre-COVID-19 Market Scenario
12.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.4 North America Market Size Estimation and Forecast By Process
12.4.1 Pre-COVID-19 Market Scenario
12.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.5 North America Market Size Estimation and Forecast By Downstream
12.5.1 Pre-COVID-19 Market Scenario
12.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.6 North America Market Size Estimation and Forecast By Upstream
12.6.1 Pre-COVID-19 Market Scenario
12.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.7 North America Market Size Estimation and Forecast By Vaccine Type
12.7.1 Pre-COVID-19 Market Scenario
12.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.8 North America Market Size Estimation and Forecast By Company Size
12.8.1 Pre-COVID-19 Market Scenario
12.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.9 North America Market Size Estimation and Forecast By Operation
12.9.1 Pre-COVID-19 Market Scenario
12.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.10 US Vaccine Contract Manufacturing Market Analysis
12.10.1 Collaboration Between GSK and Vir Biotechnology to Purchase Additional Supply of Sotrovimab
12.10.2 Pre-COVID-19 Market Scenario
12.10.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.11 Canada Vaccine Contract Manufacturing Market Analysis
12.11.1 Emergent Biosolutions Secures Multi-Year Development And Manufacturing Agreement With Providence Therapeutics For Its Mrna COVID-19 Vaccine Candidate, PTX-COVID19-B
12.11.2 Pre-COVID-19 Market Scenario
12.11.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.12 Mexico Vaccine Contract Manufacturing Market Analysis
12.12.1 First COVID-19 Vaccine Fill-Finish Manufacturing In Mexico Completed
12.12.2 Pre-COVID-19 Market Scenario
12.12.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13 Europe Vaccine Contract Manufacturing Market Analysis
13.1 EU Watchdog Okays Production Capacity Hikes For J&J, Moderna, Pfizer Vaccines
13.2 European Commission Approves Contract With Valneva To Secure A New Potential Vaccine
13.3 Europe Market Size Estimation and Forecast
13.3.1 Pre-COVID-19 Market Scenario
13.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.4 Country Market Size Estimation and Forecast
13.4.1 Pre-COVID-19 Market Scenario
13.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.5 Europe Market Size Estimation and Forecast By Process
13.5.1 Pre-COVID-19 Market Scenario
13.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.6 Europe Market Size Estimation and Forecast By Downstream
13.6.1 Pre-COVID-19 Market Scenario
13.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.7 Europe Market Size Estimation and Forecast By Upstream
13.7.1 Pre-COVID-19 Market Scenario
13.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.8 Europe Market Size Estimation and Forecast By Vaccine Type
13.8.1 Pre-COVID-19 Market Scenario
13.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.9 Europe Market Size Estimation and Forecast By Company Size
13.9.1 Pre-COVID-19 Market Scenario
13.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.10 Europe Market Size Estimation and Forecast By Operation
13.10.1 Pre-COVID-19 Market Scenario
13.10.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.11 Germany Vaccine Contract Manufacturing Market Analysis
13.11.1 Curevac Slashes COVID-19 Vaccine Production Plans
13.11.2 Pre-COVID-19 Market Scenario
13.11.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.12 UK Vaccine Contract Manufacturing Market Analysis
13.12.1 UK Reportedly Selling £200m Vaccine Plant That Never Produced A Single Dose
13.12.2 Pre-COVID-19 Market Scenario
13.12.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.13 France Vaccine Contract Manufacturing Market Analysis
13.13.1 Recipharm Secures Vaccine Manufacturing Deal With Top 10 Big Pharma And Will Provide Manufacturing Support From Facility In Kaysersberg, France
13.13.2 Pre-COVID-19 Market Scenario
13.13.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.14 Italy Vaccine Contract Manufacturing Market Analysis
13.14.1 Aenova’s Biologics And Vaccines Manufacturing Facility Expansion, Latina, Italy
13.14.2 Pre-COVID-19 Market Scenario
13.14.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.15 Spain Vaccine Contract Manufacturing Market Analysis
13.15.1 Moderna And ROVI Expand Long-Term Collaboration For The Manufacture Of MRNA Medicines Over The Next Ten Years
13.15.2 Pre-COVID-19 Market Scenario
13.15.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.16 Rest of Europe Vaccine Contract Manufacturing Market Analysis
13.16.1 Pre-COVID-19 Market Scenario
13.16.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14 Asia-Pacific Vaccine Contract Manufacturing Market Analysis
14.1 Asia Pacific Must Fix Its Broken Vaccine System
14.2 Asia-Pacific Market Size Estimation and Forecast
14.2.1 Pre-COVID-19 Market Scenario
14.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.3 Country Market Size Estimation and Forecast
14.3.1 Pre-COVID-19 Market Scenario
14.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.4 Asia-Pacific Market Size Estimation and Forecast By Process
14.4.1 Pre-COVID-19 Market Scenario
14.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.5 Asia-Pacific Market Size Estimation and Forecast By Downstream
14.5.1 Pre-COVID-19 Market Scenario
14.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.6 Asia-Pacific Market Size Estimation and Forecast By Upstream
14.6.1 Pre-COVID-19 Market Scenario
14.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.7 Asia-Pacific Market Size Estimation and Forecast By Vaccine Type
14.7.1 Pre-COVID-19 Market Scenario
14.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.8 Asia-Pacific Market Size Estimation and Forecast By Company Size
14.8.1 Pre-COVID-19 Market Scenario
14.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.9 Asia-Pacific Market Size Estimation and Forecast By Operation
14.9.1 Pre-COVID-19 Market Scenario
14.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.10 China Vaccine Contract Manufacturing Market Analysis
14.10.1 China Is Manufacturing Vaccines In Africa.
14.10.2 Pre-COVID-19 Market Scenario
14.10.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.11 India Vaccine Contract Manufacturing Market Analysis
14.11.1 Serum Institute Invests $68m In Oxford Biomedica To Expand Vector Capacity
14.11.2 Pre-COVID-19 Market Scenario
14.11.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.12 Japan Vaccine Contract Manufacturing Market Analysis
14.12.1 Japan's Takara Bio To Launch Contract Production Of Mrna Vaccines
14.12.2 Pre-COVID-19 Market Scenario
14.12.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.13 South Korea Vaccine Contract Manufacturing Market Analysis
14.13.1 Moderna, Novavax To Produce More COVID-19 Vaccines In South Korea
14.13.2 South Korea’s SK Bioscience Expands Manufacturing Agreement For Novavax’s COVID-19 Vaccine
14.13.3 Pre-COVID-19 Market Scenario
14.13.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.14 Australia Vaccine Contract Manufacturing Market Analysis
14.14.1 Novavax Hunts For Australian Manufacturer As CSL Homes In On AstraZeneca Vaccine Production
14.14.2 Australia Plans To Stop AstraZeneca Vaccine Production
14.14.3 Pre-COVID-19 Market Scenario
14.14.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.15 Rest of Asia-Pacific Vaccine Contract Manufacturing Market Analysis
14.15.1 Pre-COVID-19 Market Scenario
14.15.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15 LAMEA Vaccine Contract Manufacturing Market Analysis
15.1 PAHO Welcomes First WHO Emergency Use Listing Of COVID-19 Vaccine Produced In Latin America
15.2 Brazil And Argentina Tapped To Make mRNA Vaccines In Latin America
15.3 LAMEA Market Size Estimation and Forecast
15.3.1 Pre-COVID-19 Market Scenario
15.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.4 Country Market Size Estimation and Forecast
15.4.1 Pre-COVID-19 Market Scenario
15.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.5 LAMEA Market Size Estimation and Forecast By Process
15.5.1 Pre-COVID-19 Market Scenario
15.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.6 LAMEA Market Size Estimation and Forecast By Downstream
15.6.1 Pre-COVID-19 Market Scenario
15.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.7 LAMEA Market Size Estimation and Forecast By Upstream
15.7.1 Pre-COVID-19 Market Scenario
15.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.8 LAMEA Market Size Estimation and Forecast By Vaccine Type
15.8.1 Pre-COVID-19 Market Scenario
15.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.9 LAMEA Market Size Estimation and Forecast By Company Size
15.9.1 Pre-COVID-19 Market Scenario
15.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.10 LAMEA Market Size Estimation and Forecast By Operation
15.10.1 Pre-COVID-19 Market Scenario
15.10.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.11 Brazil Vaccine Contract Manufacturing Market Analysis
15.11.1 Pfizer, Biontech Sign On With Eurofarma Of Brazil For COVID-19 Vaccine Production
15.11.2 Pre-COVID-19 Market Scenario
15.11.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.12 South Africa Vaccine Contract Manufacturing Market Analysis
15.12.1 Janssen And Aspen Enter Deal To Manufacture Covid-19 Vaccine In Africa
15.12.2 Pre-COVID-19 Market Scenario
15.12.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.13 Saudi Arabia Vaccine Contract Manufacturing Market Analysis
15.13.1 Saudi Arabia Agrees Deal With GSK To Develop Healthcare Sector
15.13.2 Pre-COVID-19 Market Scenario
15.13.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.14 Turkey Vaccine Contract Manufacturing Market Analysis
15.14.1 Turkey Renews SK Bioscience’s Vaccine Manufacturing Certification
15.14.2 Pre-COVID-19 Market Scenario
15.14.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.15 UAE Vaccine Contract Manufacturing Market Analysis
15.15.1 Mubadala, G42 To Set Up Biopharma Manufacturing Campus In Abu Dhabi
15.15.2 Pre-COVID-19 Market Scenario
15.15.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.16 Rest of LAMEA Vaccine Contract Manufacturing Market Analysis
15.16.1 Pre-COVID-19 Market Scenario
15.16.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16 Company Profiles
16.1 Catalent
16.1.1 Company Snapshot
16.1.2 Company Overview
16.1.3 Company Financial Profile
16.1.4 Company Product/Service Benchmarking
16.1.5 Company Recent Developments
16.2 Emergent BioSolutions
16.2.1 Company Snapshot
16.2.2 Company Overview
16.2.3 Company Financial Profile
16.2.4 Company Product/Service Benchmarking
16.2.5 Company Recent Developments
16.3 GlaxoSmithKline
16.3.1 Company Snapshot
16.3.2 Company Overview
16.3.3 Company Financial Profile
16.3.4 Company Product/Service Benchmarking
16.3.5 Company Recent Developments
16.4 Lonza Group AG
16.4.1 Company Snapshot
16.4.2 Company Overview
16.4.3 Company Financial Profile
16.4.4 Company Product/Service Benchmarking
16.4.5 Company Recent Developments
16.5 Merck KGaA
16.5.1 Company Snapshot
16.5.2 Company Overview
16.5.3 Company Financial Profile
16.5.4 Company Product/Service Benchmarking
16.5.5 Company Recent Developments
16.6 Pfizer
16.6.1 Company Snapshot
16.6.2 Company Overview
16.6.3 Company Financial Profile
16.6.4 Company Product/Service Benchmarking
16.6.5 Company Recent Developments
16.7 Siegfried Holding
16.7.1 Company Snapshot
16.7.2 Company Overview
16.7.3 Company Financial Profile
16.7.4 Company Product/Service Benchmarking
16.7.5 Company Recent Developments
16.8 Sanofi
16.8.1 Company Snapshot
16.8.2 Company Overview
16.8.3 Company Financial Profile
16.8.4 Company Product/Service Benchmarking
16.9 Bavarian Nordic
16.9.1 Company Snapshot
16.9.2 Company Overview
16.9.3 Company Financial Profile
16.9.4 Company Product/Service Benchmarking
16.10 FUJIFILM Holdings Corp
16.10.1 Company Snapshot
16.10.2 Company Overview
16.10.3 Company Financial Profile
16.10.1 Company Product/Service Benchmarking
16.11 Charles River Laboratories
16.11.1 Company Snapshot
16.11.2 Company Overview
16.11.3 Company Financial Profile
16.11.4 Company Product/Service Benchmarking
16.11.5 Company Recent Developments
16.12 Samsung Biologics
16.12.1 Company Snapshot
16.12.2 Company Overview
16.12.3 Company Financial Profile
16.12.4 Company Product/Service Benchmarking
16.12.5 Company Recent Developments
16.13 AbbVie
16.13.1 Company Snapshot
16.13.2 Company Overview
16.13.3 Company Financial Profile
16.13.4 Company Product/Service Benchmarking
16.14 Thermo Fisher Scientific Inc
16.14.1 Company Snapshot
16.14.2 Company Overview
16.14.3 Company Financial Profile
16.14.4 Company Product/Service Benchmarking
16.14.5 Company Recent Developments
16.15 Eurofins Scientific
16.15.1 Company Snapshot
16.15.2 Company Overview
16.15.3 Company Financial Profile
16.15.4 Company Product/Service Benchmarking
16.15.5 Company Recent Developments
16.16 WuXi Biologics
16.16.1 Company Snapshot
16.16.2 Company Overview
16.16.3 Company Financial Profile
16.16.4 Company Product/Service Benchmarking
16.16.5 Company Recent Developments
16.17 Serum Institute of India
16.17.1 Company Snapshot
16.17.2 Company Overview
16.17.3 Company Product/Service Benchmarking
16.17.4 Company Recent Developments
16.18 Richter-Helm BioLogics
16.18.1 Company Snapshot
16.18.2 Company Overview
16.18.3 Company Product/Service Benchmarking
16.18.4 Company Recent Developments
16.19 Wacker Biotech B.V
16.19.1 Company Snapshot
16.19.2 Company Overview
16.19.3 Company Product/Service Benchmarking
16.20 Kemwell Biopharma
16.20.1 Company Snapshot
16.20.2 Company Overview
16.20.3 Company Product/Service Benchmarking
17 Conclusion
17.1 Concluding Remarks
17.2 Recommendations
List of Tables
Table 1. Global Vaccine Contract Manufacturing Market Forecast, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 2. Global Vaccine Contract Manufacturing Market Snapshot, 2022 & 2032 (US$million, CAGR %)
Table 3. Global Vaccine Contract Manufacturing Market Forecast, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 4. Global Vaccine Contract Manufacturing Market Forecast, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (V – Shaped Recovery)
Table 5. Global Vaccine Contract Manufacturing Market Forecast, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (W – Shaped Recovery)
Table 6. Global Vaccine Contract Manufacturing Market Forecast, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (U – Shaped Recovery)
Table 7. Global Vaccine Contract Manufacturing Market Forecast, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (L – Shaped Recovery)
Table 8. Global Vaccine Contract Manufacturing Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 9. Global Vaccine Contract Manufacturing Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (V – Shaped Recovery)
Table 10. Global Vaccine Contract Manufacturing Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (W – Shaped Recovery)
Table 11. Global Vaccine Contract Manufacturing Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (U – Shaped Recovery)
Table 12. Global Vaccine Contract Manufacturing Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (L – Shaped Recovery)
Table 13. Global Vaccine Contract Manufacturing Market by Process, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 14. Global Vaccine Contract Manufacturing Market by Process, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (V – Shaped Recovery)
Table 15. Global Vaccine Contract Manufacturing Market by Process, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (W – Shaped Recovery)
Table 16. Global Vaccine Contract Manufacturing Market by Process, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (U – Shaped Recovery)
Table 17. Global Vaccine Contract Manufacturing Market by Process, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (L – Shaped Recovery)
Table 18. Global Vaccine Contract Manufacturing Market by Downstream, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 19. Global Vaccine Contract Manufacturing Market by Downstream, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (V – Shaped Recovery)
Table 20. Global Vaccine Contract Manufacturing Market by Downstream, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (W – Shaped Recovery)
Table 21. Global Vaccine Contract Manufacturing Market by Downstream, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (U – Shaped Recovery)
Table 22. Global Vaccine Contract Manufacturing Market by Downstream, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (L – Shaped Recovery)
Table 23. Global Vaccine Contract Manufacturing Market by Upstream, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 24. Global Vaccine Contract Manufacturing Market by Upstream, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (V – Shaped Recovery)
Table 25. Global Vaccine Contract Manufacturing Market by Upstream, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (W – Shaped Recovery)
Table 26. Global Vaccine Contract Manufacturing Market by Upstream, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (U – Shaped Recovery)
Table 27. Global Vaccine Contract Manufacturing Market by Upstream, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (L – Shaped Recovery)
Table 28. Global Vaccine Contract Manufacturing Market by Vaccine Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 29. Global Vaccine Contract Manufacturing Market by Vaccine Type, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (V – Shaped Recovery)
Table 30. Global Vaccine Contract Manufacturing Market by Vaccine Type, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (W – Shaped Recovery)
Table 31. Global Vaccine Contract Manufacturing Market by Vaccine Type, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (U – Shaped Recovery)
Table 32. Global Vaccine Contract Manufacturing Market by Vaccine Type, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (L – Shaped Recovery)
Table 33. Global Vaccine Contract Manufacturing Market by Company Size, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 34. Global Vaccine Contract Manufacturing Market by Company Size, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (V – Shaped Recovery)
Table 35. Global Vaccine Contract Manufacturing Market by Company Size, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (W – Shaped Recovery)
Table 36. Global Vaccine Contract Manufacturing Market by Company Size, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (U – Shaped Recovery)
Table 37. Global Vaccine Contract Manufacturing Market by Company Size, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (L – Shaped Recovery)
Table 38. Global Vaccine Contract Manufacturing Market by Operation, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 39. Global Vaccine Contract Manufacturing Market by Operation, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (V – Shaped Recovery)
Table 40. Global Vaccine Contract Manufacturing Market by Operation, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (W – Shaped Recovery)
Table 41. Global Vaccine Contract Manufacturing Market by Operation, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (U – Shaped Recovery)
Table 42. Global Vaccine Contract Manufacturing Market by Operation, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (L – Shaped Recovery)
Table 43. North America Vaccine Contract Manufacturing Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 44. North America Vaccine Contract Manufacturing Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (V – Shaped Recovery)
Table 45. North America Vaccine Contract Manufacturing Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (W – Shaped Recovery)
Table 46. North America Vaccine Contract Manufacturing Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (U – Shaped Recovery)
Table 47. North America Vaccine Contract Manufacturing Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (L – Shaped Recovery)
Table 48. North America Vaccine Contract Manufacturing Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 49. North America Vaccine Contract Manufacturing Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (V – Shaped Recovery)
Table 50. North America Vaccine Contract Manufacturing Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (W – Shaped Recovery)
Table 51. North America Vaccine Contract Manufacturing Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (U – Shaped Recovery)
Table 52. North America Vaccine Contract Manufacturing Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (L – Shaped Recovery)
Table 53. North America Vaccine Contract Manufacturing Market by Process, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 54. North America Vaccine Contract Manufacturing Market by Process, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (V – Shaped Recovery)
Table 55. North America Vaccine Contract Manufacturing Market by Process, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (W – Shaped Recovery)
Table 56. North America Vaccine Contract Manufacturing Market by Process, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (U – Shaped Recovery)
Table 57. North America Vaccine Contract Manufacturing Market by Process, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (L – Shaped Recovery)
Table 58. North America Vaccine Contract Manufacturing Market by Downstream, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 59. North America Vaccine Contract Manufacturing Market by Downstream, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (V – Shaped Recovery)
Table 60. North America Vaccine Contract Manufacturing Market by Downstream, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (W – Shaped Recovery)
Table 61. North America Vaccine Contract Manufacturing Market by Downstream, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (U – Shaped Recovery)
Table 62. North America Vaccine Contract Manufacturing Market by Downstream, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (L – Shaped Recovery)
Table 63. North America Vaccine Contract Manufacturing Market by Upstream, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 64. North America Vaccine Contract Manufacturing Market by Upstream, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (V – Shaped Recovery)
Table 65. North America Vaccine Contract Manufacturing Market by Upstream, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (W – Shaped Recovery)
Table 66. North America Vaccine Contract Manufacturing Market by Upstream, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (U – Shaped Recovery)
Table 67. North America Vaccine Contract Manufacturing Market by Upstream, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (L – Shaped Recovery)
Table 68. North America Vaccine Contract Manufacturing Market by Vaccine Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 69. North America Vaccine Contract Manufacturing Market by Vaccine Type, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (V – Shaped Recovery)
Table 70. North America Vaccine Contract Manufacturing Market by Vaccine Type, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (W – Shaped Recovery)
Table 71. North America Vaccine Contract Manufacturing Market by Vaccine Type, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (U – Shaped Recovery)
Table 72. North America Vaccine Contract Manufacturing Market by Vaccine Type, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (L – Shaped Recovery)
Table 73. North America Vaccine Contract Manufacturing Market by Company Size, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 74. North America Vaccine Contract Manufacturing Market by Company Size, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (V – Shaped Recovery)
Table 75. North America Vaccine Contract Manufacturing Market by Company Size, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (W – Shaped Recovery)
Table 76. North America Vaccine Contract Manufacturing Market by Company Size, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (U – Shaped Recovery)
Table 77. North America Vaccine Contract Manufacturing Market by Company Size, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (L – Shaped Recovery)
Table 78. North America Vaccine Contract Manufacturing Market by Operation, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 79. North America Vaccine Contract Manufacturing Market by Operation, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (V – Shaped Recovery)
Table 80. North America Vaccine Contract Manufacturing Market by Operation, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (W – Shaped Recovery)
Table 81. North America Vaccine Contract Manufacturing Market by Operation, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (U – Shaped Recovery)
Table 82. North America Vaccine Contract Manufacturing Market by Operation, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (L – Shaped Recovery)
Table 83. US Vaccine Contract Manufacturing Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 84. US Vaccine Contract Manufacturing Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (V – Shaped Recovery)
Table 85. US Vaccine Contract Manufacturing Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (W – Shaped Recovery)
Table 86. US Vaccine Contract Manufacturing Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (U – Shaped Recovery)
Table 87. US Vaccine Contract Manufacturing Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (L – Shaped Recovery)
Table 88. Canada Vaccine Contract Manufacturing Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 89. Canada Vaccine Contract Manufacturing Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (V – Shaped Recovery)
Table 90. Canada Vaccine Contract Manufacturing Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (W – Shaped Recovery)
Table 91. Canada Vaccine Contract Manufacturing Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (U – Shaped Recovery)
Table 92. Canada Vaccine Contract Manufacturing Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (L – Shaped Recovery)
Table 93. Mexico Vaccine Contract Manufacturing Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 94. Mexico Vaccine Contract Manufacturing Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (V – Shaped Recovery)
Table 95. Mexico Vaccine Contract Manufacturing Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%)) (W – Shaped Recovery)
Table 96. Mexico Vaccine Contract Man
